Lee OH, et al. - Using the Korean LAA Occlusion and European Amplatzer Cardiac Plug Multi-Center Registry, researchers focused on neurological disability following ischemic cerebrovascular events in patients treated with left atrial appendage (LAA) occlusion vs those on warfarin. The LAA occlusion vs warfarin groups had 37.5% vs 58.8% as percentages of disabling cerebrovascular events at discharge, 20.8% and 42.6% at 3 months, and 12.5% and 39.7% at 12 months, respectively. Unlike the warfarin group, a significant decrease in modified Rankin scale between discharge and 12 months was shown by patients in the LAA occlusion group. Findings revealed more favorable ischemic cerebrovascular events in patients who earlier underwent percutaneous LAA occlusion for nonvalvular atrial fibrillation vs patients on warfarin.